HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed non-binding term sheets for USD 30 million in non-dilutive financing to acquire interventional psychiatry clinics, including five operational clinics in the Western US.
With this acquisition, HOPE Therapeutics aims to create a unified network of clinics providing ketamine therapy and other treatments for suicidal depression, treatment-resistant depression, and post-traumatic stress disorder. The company plans to combine pharmaceutical therapy, FDA-approved medical technologies, digital therapeutics, and access to clinical trials for new treatments.
HOPE Therapeutics is developing a network of clinics focused on ketamine and other therapies for neurological and psychiatric disorders. The company aims to submit its new drug application to the FDA for its ketamine therapy to treat suicidal depression in 2H 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.